NASDAQ:FIXX - Homology Medicines Stock Price, Forecast & News

Homology Medicines trades on the NASDAQ under the ticker symbol "FIXX."

Homology Medicines Inc (NASDAQ:FIXX) released its quarterly earnings data on Thursday, August, 8th. The company reported ($0.61) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.55) by $0.06. The business had revenue of $0.39 million for the quarter, compared to the consensus estimate of $1 million. Homology Medicines had a negative net margin of 4,740.81% and a negative return on equity of 43.33%. View Homology Medicines' Earnings History.

Homology Medicines is scheduled to release their next quarterly earnings announcement on Tuesday, March 10th 2020. View Earnings Estimates for Homology Medicines.

6 Wall Street analysts have issued 12-month target prices for Homology Medicines' shares. Their forecasts range from $29.00 to $37.00. On average, they anticipate Homology Medicines' share price to reach $33.00 in the next twelve months. This suggests a possible upside of 86.8% from the stock's current price. View Analyst Price Targets for Homology Medicines.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Homology Medicines in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Homology Medicines.

News headlines about FIXX stock have been trending somewhat positive recently, according to InfoTrie Sentiment. The research group scores the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Homology Medicines earned a news sentiment score of 1.6 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the near future. View News Stories for Homology Medicines.

Homology Medicines saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 3,510,000 shares, an increase of 15.1% from the January 15th total of 3,050,000 shares. Based on an average daily volume of 352,500 shares, the days-to-cover ratio is presently 10.0 days. Approximately 11.6% of the shares of the company are sold short. View Homology Medicines' Current Options Chain.

Some companies that are related to Homology Medicines include Axsome Therapeutics (AXSM), Intercept Pharmaceuticals (ICPT), Myokardia (MYOK), Genmab A/S (GMAB), Agios Pharmaceuticals (AGIO), Allakos (ALLK), Apellis Pharmaceuticals (APLS), Alkermes (ALKS), ChemoCentryx (CCXI), Deciphera Pharmaceuticals (DCPH), Taro Pharmaceutical Industries (TARO), Insmed (INSM), Amicus Therapeutics (FOLD), Uniqure (QURE) and Arena Pharmaceuticals (ARNA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Homology Medicines investors own include InterDigital Wireless (IDCC), Bank of Hawaii (BOH), Editas Medicine (EDIT), Heron Therapeutics (HRTX), Inovio Pharmaceuticals (INO), Pfizer (PFE), Stag Industrial (STAG), Gilead Sciences (GILD), Nektar Therapeutics (NKTR) and Novavax (NVAX).

(FIXX) raised $100 million in an IPO on Wednesday, March 28th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Evercore ISI acted as the underwriters for the IPO and BTIG was co-manager.

Homology Medicines' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include 5AM Venture Management LLC (12.57%), FMR LLC (4.92%), State Street Corp (1.86%), Geode Capital Management LLC (0.81%), Victory Capital Management Inc. (0.81%) and Victory Capital Management Inc. (0.80%). Company insiders that own Homology Medicines stock include Albert Seymour, Arthur Tzianabos, James E Flynn, Kush Parmar, Siyamak Rasty, Timothy P Kelly, Ventures Iv LP 5Am, Vida Ventures, Llc and W Bradford Smith. View Institutional Ownership Trends for Homology Medicines.

FIXX stock was sold by a variety of institutional investors in the last quarter, including Credit Suisse AG, Sofinnova Investments Inc., UBS Group AG, Victory Capital Management Inc., State Street Corp, Sectoral Asset Management Inc, Victory Capital Management Inc. and Citigroup Inc.. Company insiders that have sold Homology Medicines company stock in the last year include Albert Seymour, Arthur Tzianabos, James E Flynn, Kush Parmar, Siyamak Rasty, Timothy P Kelly and W Bradford Smith. View Insider Buying and Selling for Homology Medicines.

FIXX stock was bought by a variety of institutional investors in the last quarter, including 5AM Venture Management LLC, FMR LLC, California Public Employees Retirement System, Amia Capital LLP, Virtus ETF Advisers LLC, Geode Capital Management LLC, Goldman Sachs Group Inc. and Alpine Global Management LLC. Company insiders that have bought Homology Medicines stock in the last two years include James E Flynn and Vida Ventures, Llc. View Insider Buying and Selling for Homology Medicines.

Shares of FIXX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of FIXX stock can currently be purchased for approximately $17.67.

Homology Medicines has a market capitalization of $778.10 million and generates $3.68 million in revenue each year. The company earns $-57,220,000.00 in net income (profit) each year or ($2.00) on an earnings per share basis. Homology Medicines employs 124 workers across the globe.View Additional Information About Homology Medicines.

The official website for Homology Medicines is http://www.homologymedicines.com/.

Homology Medicines' mailing address is ONE PATRIOTS PARK, BEDFORD MA, 01730. The company can be reached via phone at 781-301-7277.